Versant Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Versant Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,053	Closed	-$42.4K	–	2753
2026 Q1	$42.4K	Buy	1,053 +480	+84%	+$10.3K	﹤0.01%	1338
2025 Q4	$14.4K	Hold	573	–	–	﹤0.01%	1831
2025 Q3	$13K	Sell	573 -31	-5%	-$723	﹤0.01%	1819
2025 Q2	$10.5K	Buy	604 +438	+264%	+$8.11K	﹤0.01%	1876
2025 Q1	$3.63K	Sell	166 -103	-38%	-$2.85K	﹤0.01%	2143
2024 Q4	$8.58K	Buy	+269	New	+$8.09K	﹤0.01%	1491
2023 Q3	–	Sell	-14	Closed	-$1.27K	–	1943
2023 Q2	$1.27K	Buy	+14	New	+$1.21K	﹤0.01%	1531

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Versant Capital Management's APLS Position: Q2 2026 in Review

Versant Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,053 shares — an estimated $42.4K sold.

Versant Capital Management first reported a position in APLS in Q2 2023 and held it in 7 quarters. The position peaked at $42.4K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Versant Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Versant Capital Management sold 1,053 Apellis Pharmaceuticals shares in Q2 2026, an estimated $42.4K.
Versant Capital Management first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 7 quarters.
Versant Capital Management's Apellis Pharmaceuticals position peaked at $42.4K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.